VFA
HRTX icon

Virtus Fund Advisers’s Heron Therapeutics HRTX Stock Holding History

Virtus Fund Advisers’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-1,658
Closed -$20K – 1499
2014
Q2 		$20K Buy
+1,658
New +$19.8K ﹤0.01% 2437

Other funds holding HRTX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Virtus Fund Advisers's HRTX Position: Q3 2014 in Review

Virtus Fund Advisers sold out of Heron Therapeutics (HRTX) in Q3 2014, closing a stake of 1,658 shares — an estimated $20K sold.

Virtus Fund Advisers first reported a position in HRTX in Q2 2014 and held it in 1 quarter. The position peaked at $20K in Q2 2014. 59 funds tracked by Wall St. Rank hold HRTX as of Q3 2014.

  • Virtus Fund Advisers reported no remaining Heron Therapeutics position as of Q3 2014 after selling out during the quarter.
  • Virtus Fund Advisers sold 1,658 Heron Therapeutics shares in Q3 2014, an estimated $20K.
  • Virtus Fund Advisers first reported a position in Heron Therapeutics in Q2 2014 and held it in 1 quarter.
  • Virtus Fund Advisers's Heron Therapeutics position peaked at $20K in Q2 2014.
  • 59 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2014.

Based on Virtus Fund Advisers's 13F filing for Q3 2014, filed 31 Oct 2014.